We have six projects in clinical development and five projects in late discovery or pre-clinical development. We target some of the largest epithelial cancer indications, such as colorectal and lung cancers
Our clinical pipeline comprises five immune-oncology projects targeting PD1 (Sym021), LAG3 (Sym022), TIM3 (Sym023) and CD73 (Sym024) and two RTK oncology projects, EGFR (Sym004) and MET (Sym015). We are also advancing several discovery or pre-clinical projects, including FLT3 (Sym027), AXL (Sym028) and CD40 (Sym029) projects. Status and future plans are outlined in this pipeline section.
|We target some of the largest epithelial cancer indications, such as colorectal and lung cancers.|
In our clinical-stage immuno-oncology program with six targets, four projects are in Phase 1 development and one in the IND enabling process.
In our clinical stage RTK oncology projects, one is ready for phase III development and the other is finalizing phase IIa.
In addition to our clinical trials, we maintain extensive proprietary and partnered discovery and preclinical activities to continue to realize the potential of our technology platform.
What are antibodies?
Antibodies are Y-shaped proteins produced by specialized cells of the body’s immune system. Antibodies can identify and bind disease-specific antigens found on bacteria, viruses, and cancer cells. Once attached to the antigen, antibodies can recruit other parts of the immune system to help neutralize the cells containing the antigen. The place on the antigen where the antibody binds is called an epitope. Researchers can design antibodies to target a certain antigen. Antibodies can be made in large amounts known as monoclonal antibodies (mAbs). Monoclonal antibodies are a well-established drug class today used to treat many diseases, including cancer.